Recent News

• 04.11.2025 - Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
• 04.11.2025 - Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
• 04.11.2025 - Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
• 04.10.2025 - Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.10.2025 - Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.10.2025 - Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.27.2025 - Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
• 03.27.2025 - Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
• 03.27.2025 - Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
• 03.26.2025 - Alex Thompson

Recent Filings

• 04.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - 8-K Current report
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities